DYV-700 Gout Abstract

Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy and Safety Study of a Transdermal Alkalinizing and Pain Relieving Treatment for Acute Gout Pain

Objectives:

Gout is characterized by a build-up of monosodium urate (MSU) crystals in and around the joints. MSU crystal formation and dissolution is affected by pH. There are reports in the literature of the use of alkalization agents, such as sodium bicarbonate, to treat gout. Theoretically, an alkalinizing agent such as sodium bicarbonate (baking soda) may increase the systemic and/or local pH and may allow pH sensitive uric acid crystals to dissolve resulting in temporary relief of pain and shortening duration of a gout flare, however oral sodium bicarbonate use causes intolerable gastrointestinal side-effects. The objective of this study was to determine if sodium bicarbonate in a patented transdermal drug delivery system (Dyve Biosciences, Thousand Oaks,CA) can effectively and safely reduce pain and shorten duration of an acute gout flare. This delivery system has been shown to effectively deliver sodium bicarbonate transdermally in prior animal and human studies.